15 Lessons from 15 Years in Healthcare Technology: Nelson Advisors partner Lloyd Price reflects on his journey from Founder to Banker
- Nelson Advisors
- 1 hour ago
- 9 min read
Fifteen years ago I walked into healthcare technology believing that good software, priced sensibly, would sell itself to a health system crying out for modernisation. I was wrong in almost every way that mattered, and right about the only thing that counted:, the problem was worth a career.
Between co-founding Zesty in 2012 and building it into one of the UK's leading patient portals, negotiating a Value Added Reseller agreement with Cerner that took three years to close and multiplied our annual revenue significantly, and raising capital from US, European & UK Venture Capital Funds across five very different vintages, I accumulated scar tissue that I now put to work advising founders, investors and boards at Nelson Advisors.
Here are the fifteen lessons I wish someone had told me back in the summer of 2011.
1. The NHS doesn't buy products. It adopts people.
Every NHS sale I ever closed came down to a person, not a procurement portal. Behind each contract was a clinician who staked their reputation on us, an operations manager who wanted their Monday mornings back and an IT director who needed reassurance we wouldn't embarrass them. The framework I eventually built for selling into the NHS starts here: you are managing hearts, minds and egos. Hearts are won with patient stories and a credible mission. Minds are won with evidence, references and a business case that survives the finance committee. Egos are the silent deal killers: every stakeholder needs to feel the decision was theirs. Ignore any one of the three and your deal will die quietly in a corridor you never knew existed.
2. Map the four Ps before you write a line of code.
The second half of my NHS framework is people, processes, pathways and policies. People: who touches your product, from booking clerk to consultant, and what does each one lose or gain? Processes: which existing workflows do you replace, and who owns them today? Pathways: where does the patient actually travel through the system, and does your product shorten that journey or quietly lengthen it? Policies: which national mandates, information governance rules and clinical safety standards (DCB0129 and DCB0160 became second nature at Zesty) can sink you, and which can you surf? Products that map cleanly onto all four Ps get adopted. Products that fight even one of them get piloted, praised and shelved.
3. Patience is a competitive weapon.
The Cerner Value Added Reseller agreement took three years to negotiate. Three years of legal reviews, commercial re-scoping, security assessments, personnel changes on both sides and moments when the deal looked dead. When it finally landed, it multiplied Zesty's annual revenue significantly. The lesson isn't that big partnerships are slow, although they are. It's that patience is a moat. Most startups couldn't survive a three-year negotiation, so most never start one. If you can structure your business to endure long cycles, you compete for prizes most of the market has already given up on. We kept selling directly the whole time, which meant we negotiated from steadiness rather than desperation. Desperation is visible across a boardroom table and it is expensive.
4. Partner with giants, but keep your spine.
A reseller agreement with a global EHR vendor transforms your distribution overnight and it can just as easily transform you into a feature. Through three years of negotiation we held two lines: we kept our own direct customer relationships and we kept our product roadmap under our own control. Everything else was negotiable. Giants respect counterparties who know exactly which terms are existential and concede gracefully on the rest. The deals that go wrong are the ones where a startup, dazzled by the logo, trades away its independence for a forecast. A partnership should multiply what you already are, not replace it.
5. The strongest founding teams stand on three legs.
Healthtech founding teams need technical, clinical and commercial expertise. The balance between them matters more than the brilliance of any one. Two engineers and no clinician will build something elegant that no ward will use. Two doctors and no commercial founder will build something clinically perfect that no one can buy. At Zesty we learned to treat the three disciplines as a permanent negotiation: the technical voice asks what is buildable, the clinical voice asks what is safe and useful, the commercial voice asks what is sellable. When one leg dominates, the company tilts. The founders I now advise at Nelson Advisors hear the same question from me first: which leg is missing and how quickly can you add it?
6. Venture Capital speaks three dialects.
I raised from US, European and UK funds, and they are different animals. US investors bought the vision and pushed us to think bigger, faster; their risk appetite was a gift and their expectations of growth were relentless. European funds wanted structure, unit economics and a path to profitability earlier in the story. UK investors knew the NHS intimately, which made them both the easiest to brief and the hardest to excite, because they had seen so many healthtech companies drown in eighteen-month sales cycles. None of these dialects is wrong. The skill is matching the investor to the chapter of the company you are actually in, not the chapter on your slide deck.
7. The market you raise in is not the market you deserve.
I personally raised as a Founder in 2012, 2015, 2018, 2021 and 2022, two different HealthTech companies but the same customer, NHS hospitals and ICB's.. In 2012 digital health was a curiosity. By 2015 it was a category. By 2018 it was crowded. In 2021 capital chased anything with "health" and "platform" in the deck, and in 2022 the window slammed shut with brutal speed. The lesson: raise when the market is open, not when your model says you need to. Take more than you think you need in the good years. The founders who treated 2021's exuberance as a verdict on their brilliance met 2022 with nine months of runway and a valuation nobody would defend.
8. Ride the wave, but anchor to the problem.
In fifteen years I watched the quantified self movement, blockchain, robotic process automation, patient self-management and now artificial intelligence each take a turn as the future of healthcare. Some waves left real infrastructure behind; others left only conference lanyards. The companies that endured, through every wave, were anchored to a timeless problem: patients want access, clinicians want time, systems want capacity. At Zesty we let the waves reprice our story and never let them redefine our product. When blockchain was the answer to everything, we kept building appointment booking and records access. Unfashionable and it compounded. Chase the wave and you refound your company every three years. Anchor to the problem and every wave eventually breaks in your favour.
9. Patients are the most underused resource in healthcare.
The deepest conviction I carried through Zesty is that the patient is an untapped workforce. Every appointment a patient books, cancels or reschedules themselves is an admin task the system no longer performs. Every record a patient reads is a phone call not made. Patient self-management was treated as a nice-to-have for most of my career; the pandemic revealed it as core infrastructure. The economics are unanswerable: the NHS cannot hire its way out of demand, but it can enrol millions of willing patients into their own care. Build products that give patients real agency, not engagement theatre, and you are aligned with the only sustainable direction healthcare can travel.
10. Revenue quality beats revenue quantity.
Early on I celebrated every pound equally. I learned to grade revenue instead. A multi-year contract with a trust that has deployed, integrated and clinically embedded your product is worth several times a pilot fee, whatever the invoice says. Pilots flatter your topline and starve your focus; the NHS has a hundred ways to trial something forever. We learned to ask one question before every deal: does this contract make the next contract easier? Reference sites, framework listings and integration depth compound. One off innovation-fund projects do not. When Cerner examined our business over those three years, it was the quality of our recurring NHS revenue, not its headline size, that carried the negotiation.
11. Cash cycles must outlast sales cycles.
An NHS sales cycle runs twelve to eighteen months on a good day. Procurement frameworks, business cases, information governance reviews and committee calendars all move at institutional speed and no amount of founder urgency accelerates them. The arithmetic is unforgiving: if your runway is shorter than your sales cycle, you are already insolvent and simply haven't noticed. We planned Zesty's fundraising around this truth, raising for the pipeline we could see, plus the slippage we knew was coming. Twice that discipline saved the company. Optimism is a fine culture and a fatal treasury policy.
12. Compliance is a feature, not a tax.
Clinical safety cases, information governance, data protection, penetration testing: I watched competitors treat these as bureaucratic friction to be minimised. We learned to treat them as product. Every certification became a sales asset, every safety case a reason a cautious CIO could say yes. In consumer software, compliance slows you down. In healthcare, it is the price of admission and, done well, a moat, because most startups do it badly and grudgingly. The day an NHS information governance lead told us our documentation was the best she had seen, I knew it closed more deals than any feature we shipped that year.
13. Let others take the credit. Customers are your best sales people.
The ego management layer of selling to the NHS deserves its own lesson. Your product will succeed inside a trust only if internal champions adopt it as their project, their innovation, their case study. That means the transformation lead presents the results at the conference, the clinical director's name goes on the paper, and your logo sits quietly at the bottom of the slide. It is remarkable how far a company can go when it lets its customers be the heroes of the story it is writing.
14. Exit windows open rarely. Respect them.
Selling Zesty taught me that exits, like fundraises, are priced by the weather as much as the company. Strategic appetite, public market sentiment and sector momentum align only occasionally and the alignment never lasts. Founders routinely decline good offers in good markets while waiting for great offers that belong to markets which no longer exist. My advice now, wearing my Nelson Advisors hat, is unromantic: know what an acceptable outcome looks like before anyone asks, revisit it annually and when a window opens onto that outcome, take it seriously. The counterfactual great exit is a story; the actual good exit is capital, freedom and a foundation for whatever you build next.
15. The mission is the moat around you.
Healthcare technology is slower, harder and more regulated than almost any other sector a founder could choose. The compensating asset is meaning. Through every funding winter, stalled negotiation and shelved pilot, what kept the Zesty team intact was the knowledge that the product helped real patients see a doctor sooner. Mission is not a poster in the office; it is retention strategy, recruitment advantage and personal fuel. Fifteen years in, having seen five hype cycles and every flavour of market, I am more convinced than ever: the founders who last in this industry are the ones who would find the problem worth solving even if the exit never came. Ironically, they are usually the ones who get the exit.
After fifteen years, the technology has changed beyond recognition; the lessons barely at all. Healthcare rewards the patient, in every sense of the word.
Nelson Advisors > European HealthTech, MedTech, Digital Health Investment Banking
Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, MedTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk
Follow Nelson Advisors LinkedIn Page > https://www.linkedin.com/company/nelson-advisors/
Nelson Advisors regularly publish Thought Leadership articles covering market insights, industry trends, deal commentary, market analysis & predictions. https://www.healthcare.digital
Nelson Advisors publish Europe's Leading Healthcare Technology Investment Banking Newsletter every week, join 5000+ HealthTech and MedTech subscribers today! https://lnkd.in/e5hTp_xb
#VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #NelsonAdvisors #HealthTech #MedTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #FemTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #Canada
Nelson Advisors LLP
Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT
Meet Nelson Advisors @ 2026 Events
Digital Health Rewired > March 2026 > Birmingham, UK
NHS ConfedExpo > June 2026 > Manchester, UK
HLTH Europe > June 2026, Amsterdam, Netherlands
HIMSS AI in Healthcare > July 2026, New York, USA
Bits & Pretzels > September 2026, Munich, Germany
World Health Summit 2026 > October 2026, Berlin, Germany
HealthInvestor Healthcare Summit > October 2026, London, UK
HLTH USA 2026 > October 2026, USA
Barclays Health Elevate > October 2026, London, UK
Web Summit 2026 > November 2026, Lisbon, Portugal
MEDICA 2026 > November 2026, Düsseldorf, Germany
Venture Capital World Summit > December 2026 Toronto, Canada
Comments